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Parkinson's disease (PD) is a debilitating neurodegenerative disorder that afflicts 1% of people aged over 65 (Lang and Lozano, 1998a) . Pathologically, the disease is characterised by a progressive degeneration of the dopaminergic (DA) neurones of the substantia nigra pars compacta (SNc). Currently, treatment of PD is focused on dopamine replacement therapy using the dopamine precursor levodopa (L-DOPA) and / or dopamine receptor agonists, which can provide dramatic amelioration of PD motor symptoms in the early stages of this disease (for review see Schapira, 2005) .
However, prolonged use of these agents is associated with a long-term decline in efficacy and a number of severe motor and cognitive side-effects (Olanow and Jankovic, 2005) . Moreover, these treatments do nothing to halt the progression of nigral neuronal loss. Delaying or slowing the progression of PD would delay the need for L-DOPA therapy; therefore the development of neuroprotective strategies may play an important role in preventing the onset and reducing the severity of L-DOPArelated adverse effects (Olanow and Jankovic, 2005) . Despite extensive research however, no current treatments for PD have clearly established neuroprotective effects and/or slow disease progression.
The degeneration of nigral DA neurones in PD is thought to result from a complex interplay of factors including oxidative stress, mitochondrial dysfunction and defects in the ubiquitin-proteasome system (Jenner and Olanow, 1998) . Interestingly, anatomical and electrophysiological evidence exists for a direct excitatory projection from the subthalamic nucleus (STN) to DA neurones in the SNc (Smith et al, 1990; Iribe et al, 1999) . Considerable attention has focused on this pathway based on the discovery that the STN becomes overactive as a consequence of striatal dopamine depletion in PD, giving rise to the hypothesis that increased glutamate release onto nigral DA neurones may contribute to the continued degeneration of the nigrostriatal system (Rodriguez et al, 1998) . Thus, pharmacological agents that negatively modulate glutamate transmission in the basal ganglia (BG) have been proposed as potential neuroprotective strategies for PD treatment (Nicoletti et al, 1996) . In support of this, several studies have reported a neuroprotective action following blockade of ionotropic N-methyl-D-aspartate receptors (NMDAR) in experimental models of Parkinsonism (Turski et al, 1991; Sonsalla et al, 1998; Blandini et al, 2001 ). However, the clinical usefulness of these compounds is limited by their association with severe cognitive and motor side-effects (Lee et al, 1999) Thus, recent research attention has focused on metabotropic glutamate receptors (mGluRs), which form part of the class C heptahelix G-protein-coupled receptor (GPCR) family and which by virtue of their differential expression and unique subcellular localisations play a number of key neuromodulatory roles in the mammalian brain (see Conn et al, 2003) . To date, eight mGluR genes have been cloned and divided into three subtypes based on their sequence homology, signal transduction mechanisms and pharmacological profiles (for review, see Conn and Pin, 1997) . Group I (mGluR1 and 5) are primarily expressed in postsynaptic elements of neurones where they positively modulate neuronal excitability. In contrast, Group II (mGluR2 and 3) and Group III mGluR (mGluR4, 6, 7 and 8) are presynaptically localised and negatively modulate the release of neurotransmitters, including glutamate (Cartmell and Schoepp, 2000) . Interestingly, electrophysiological studies have shown that selective activation of Group III mGluR inhibits excitatory transmission onto nigral DA neurones (Wigmore and Lacey, 1998; Katayama et al, 2003) . Furthermore, Valenti and colleagues (2005) have recently shown that activation of Group III mGluR, and in particular mGluR4, directly modulates glutamate transmission at STN: SNc synapses. This raises the possibility that selective activation of Group III mGluR may protect nigral neurones against glutamate excitotoxicity and slow disease progression in PD. In support of this, selective activation of Group III mGluR has been reported to attenuate excitatory amino acidmediated excitotoxic neuronal death both in vitro and in vivo (Lafon-Cazal et al, 1999a; Bruno et al, 2000) . Furthermore, L-AP4 has recently been reported to be neuroprotective in vitro against the pesticide toxin rotenone, which has been strongly implicated in the pathogenesis of PD (Jiang et al, 2006) . We have previously reported preliminary data suggesting that L-AP4 is neuroprotective against 6-hydroxydopamine (6-OHDA) toxicity in vivo (Vernon et al, 2005) . The aim of the current study was to extend these initial findings and characterise extensively the neuroprotective effects of Group III mGluR activation using a rodent 6-OHDA model of PD.
Materials and Methods

Animals
A total of 44 male Sprague-Dawley rats (Harlan, UK) weighing 250-270g on the day of surgery were housed in groups of three at 21 ± 1˚C on a 12h light: dark cycle (lights on 0700 h, lights off 1900 h). Standard rat chow and drinking water was available ad libitum throughout the study. All animal experiments were carried out in accordance with the Home Office Animals (Scientific procedures) Act, UK, 1986.
Stereotaxic implantation of guide cannulae
Under isoflurane anaesthesia (5% for induction, 1-3% for maintenance in oxygen, flow rate 2 L/min), rats were placed in a stereotaxic frame (David Kopf instruments, Tujunga, USA), on a thermostatically controlled heated mat. Animals then received 0.1 ml s.c injection of Marcain (AstraZeneca, Chester, UK) for analgesia and 5 ml of 4% glucose in 0.18% saline administered by i.p injection to prevent dehydration. A midline incision was made along the scalp and the skin retracted to expose the parietal bones for drilling. Stainless steel guide cannulae (26-gauge, Plastics One, Roanoke, USA) were stereotaxically implanted unilaterally 1 mm above the left SNc via a burr hole at the following co-ordinates, AP: -3.0 mm and ML: +2.5 mm (relative to bregma), DV: -7.6 mm (relative to dura), with the incisor bar set 5.0 mm above the interaural line (Paxinos and Watson, 1986) . Cannulae were anchored in place using dental resin (Kemdent Simplex Rapid, Swindon, UK) and three screws inserted into the skull. Indwelling cannulae were kept patent by the insertion of a stainless steel dummy cannula (26-gauge, Plastics One, Roanoke, USA). Post-surgery, animals were placed in a heated recovery chamber and allowed to recover from the anaesthetic.
Post-operative care included individual caging and a mashed diet.
Induction of substantia nigra lesions
After a minimum 10 day recovery period, unilateral lesions of the left SNc were created by infusion of 12 µg 6-hydroxydopmine hydrobromide (6-OHDA, free base, Sigma-Aldrich Ltd. Poole, UK) in 4 µl 0.1% ascorbic acid saline solution in the conscious animals. To avoid degradation, 6-OHDA was prepared fresh for each experiment, kept on ice and protected from light. Infusions were made through a 26-gauge stainless steel injection cannula, inserted through and extending 1 mm below the tip of the indwelling guide cannula, attached with flexible tubing (Portex, Hythe, UK) to a 10 µl 700 series Hamilton syringe mounted on a motorised Harvard micropump (Harvard Apparatus, Edenbridge, UK). Infusions were made at a rate of 2 µl / min followed by a 2 minute equilibration time, during which the needle remained in place. Sham-lesioned controls received identical surgery to lesioned animals but received intranigral infusions of 4 µl 0.1 ascorbic acid saline instead of 6-OHDA, administered as described for 6-OHDA lesioning.
Intranigral drug administration
L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4) and (RS)-α-methylserine-Ophosphate (MSOP) were dissolved in PBS (mM: NaCl 137; KCl 2.7; KH 2 PO 4 1.8; Na 2 HPO 4 10, pH 7.4) to produce a 5 mM stock solution, which was then serially diluted in PBS to produce the desired concentrations for intranigral injection and the pH adjusted to 7.4. Drugs were then aliquoted and frozen and a fresh vial used on each day of administration. In all treatment groups intranigral injections (4 µl) of each mGluR ligand were made using a 26-gauge stainless steel injection cannula, inserted through the indwelling guide cannula as described above. Drug infusions were made over a period of 2 min, followed by an equilibration period of 2 min during which time the needle remained in place. In all cases, control animals received an equivalent volume of PBS vehicle. Unless otherwise stated, L-AP4 was administered one hour prior to the 6-OHDA neurotoxin.
Brain tissue preparation for analysis of integrity and functionality of the nigrostriatal tract
In all treatment groups, one hour after the final injection, animals were sacrificed by decapitation and the brains quickly dissected out onto a chilled platform. Using a rodent brain matrix, each brain was then cut coronally at the level of the infundibular stem (-4.16 mm from bregma) to produce a fore-and hindbrain block containing the corpus striatum and SNc, respectively. At this point visual examination of needle tracts was made to confirm correct cannula placement. All animals that showed incorrect placement were excluded from the study. Hindbrain blocks were fixed in 4% paraformaldehyde for 5 days, cryoprotected in 30% sucrose for 24-48 h and then stored desiccated at -80˚C until subsequent cryostat sectioning. Serial coronal sections were cut on a cyrostat, (Bright Instruments, Cambridge, UK) maintained at -22˚C, throughout the rostral to caudal extent of the SNc (-4.80 to 6.30 mm from bregma; Paxinos and Watson, 1986) . Free-floating sections were collected and stored in 1 M PBS (pH 7.4) containing 0.05% sodium azide as a preservative until immunostaining. From the forebrain blocks, the left and right striata were quickly dissected out using the corpus callosum as a guide, snap-frozen and stored at -80˚C until biochemical analysis of monoamine content.
Histological analysis of the integrity of the nigrostriatal tract
Tyrosine hydroxylase immunostaining with Nissl counter-stain
To quantify the number of dopaminergic neurones in the SNc following 6-OHDA lesioning in vehicle and drug-treated animals, immunostaining for tyrosine hydroxylase immunoreactivity (TH-IR), the rate-limiting enzyme in DA synthesis, was performed as previously described using a standard immunoperoxidase method (Vernon et al, 2005) . Briefly, free-floating sections were washed in 1 M PBS (pH 7.4, 3 x 5 min). Endogenous peroxidase activity was quenched by incubating sections in 1% hydrogen peroxide solution for 30 min followed by washing in 1M PBS containing 0.1% triton X-100 for 15 min. Non-specific biding was blocked by incubating sections in 3% normal goat serum (NGS, MP Biomedicals, Eschwage, Germany) diluted in 1M PBS for 60 min. Sections were then incubated with the TH primary antibody (rabbit polyclonal, AB151 Chemicon Europe, Chandlers Ford, UK) diluted 1:3000 in PBS plus 0.1% triton and 3% NGS for 18 h at room temperature.
Subsequently, sections were washed in PBS (3 x 5 min) and incubated with biotinylated secondary antibody (goat α -rabbit IgG, Vector Labs, Peterborough, UK) diluted 1:200 in 1M PBS for 2 h followed by washing in PBS (3 x 5 min). Sections were incubated for a further hour in horseradish peroxidase conjugate (Vectastain Elite ABC Kit, Vector Labs, Peterborough, UK), again followed by washing in 1M PBS (3 x 5 min). Antibody binding was then visualised using a 3'3-diaminobenzidine (DAB) peroxidase staining kit (DAB peroxidase kit SK-4100, Vector Labs, Peterborough, UK) as per the manufacturer's instructions, followed by washing in distilled water. Free-floating immunostained sections were mounted onto polylysinecoated slides (VWR, UK) and allowed to adhere by air-drying. Mounted sections were then counterstained in 0.1% cresyl-fast violet (CFV) for 2 min and rinsed with tap water before dehydration through a series of graded alcohol and xylene solutions, followed by application of coverslips using DPX mounting medium. Negative controls were also performed in which 1M PBS was substituted for the primary antibody. When this was done no immunostaining was observed, confirming the specificity of the TH antibody. 
Neuronal N immunostaining
Image capture and analysis
Quantitative assessment of TH-IR and NeuN cell number
Images of nigral cells displaying robust TH-IR were captured using a JVC digital camera attached to Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan) at x100 magnification. Quantitative counting of the number of TH-IR cell bodies in the SNc was performed manually using Image Pro Plus v5.0 image analysis software (Datacell, Finchampstead, UK) . Initially, in all treatment groups, TH-IR cell bodies were counted in the contralateral and ipsilateral hemispheres of the brain at region B of the SNc (-5.30 mm from bregma) as defined by Carmen et al, (1991) and with reference to a standard rat brain atlas (Paxinos and Watson, 1986) . This region was chosen since the SNc and the nearby ventral tegmental area (VTA) are clearly separated by the medial terminal nucleus (MTN) of the accessory optic tract level. In each section, the region of the SNc was delineated by examination of the shape and distribution of TH-IR cells, at low magnification (x40) with reference to previous descriptions of these patterns (Carmen et al, 1991) and to a standard rat brain atlas (Paxinos and Watson, 1986) . Images were then subsequently captured at x100 magnification for quantitative cell counting using Image Pro Plus v.5.0. On captured images, the SNc was defined by manually drawing an area of interest (AOI) and cell counting then performed within that area only. Prior to analysis, operators were assessed for consistency of AOI drawing. Furthermore, the AOI drawn for each stereotaxic level of the SNc was 'saved' such that it could be consistently applied to each section counted at each stereotaxic level.. Only cells that were intact and displayed a robust TH-IR with a nucleus and a clear cytoplasm and axonal processes were counted. Cells that appeared severely deformed were not included (Yuan et al., 2005) . For each animal 4-5 adjacent sections were counted at level B and these were pooled to give a mean cell count for each individual animal. These counts were further pooled to give a total mean cell count for the contralateral and ipsilateral hemispheres in each treatment group. In all cases the lesion size was then expressed as a mean percentage loss compared to the contralateral side. This approach to cell counting has been used previously to ensure that comparable rostral to caudal levels of the SNc are sampled between animals (Vernon et al, 2005; Yuan et al, 2005) and the extent of cell loss at this point is reflective of cell loss throughout the entire structure (Yuan et al, 2005) . Furthermore, this approach prevents errors in counting the numbers of cells residing in the SNc and VTA. As a further control, cell counts were re-assessed by a second operator, blind to the treatment group in the same manner and the data compared for consistency.
Once this analysis was complete in order to rigorously assess loss or neuroprotection of TH-IR throughout the entire SNc structure, cell counting was performed in all treatment groups at the other stereotaxic regions of the SNc, defined A, C, D, and E (-4.80, -5.30, -5.80 and -6.30mm from bregma, respectively) by Carmen et al, (1991) , to ensure complete sampling of the entire SNc structure.
Quantitative counting of TH-IR cells was performed in the same manner as described above, using Image Pro Plus v5.0 (Datacell, Finchampstead, UK) with care taken to clearly delineate the SNc from the nearby VTA by examination of the shape and distribution of TH-IR cells, at low magnification (x40) as previously described (Carmen et al, 1991) and with reference to the standard rat brain atlas (Paxinos and Watson, 1986) . Images were then subsequently captured at x100 magnification for quantitative cell counting using Image Pro Plus v.5.0 as described above. . As before, 
Biochemical analysis of nigrostriatal tract functionality by measurement of striatal monoamines using HPLC-ECD
Striatal monoamine content was analysed using HPLC-ECD, as described previously (Vernon et al, 2005) . Briefly, the left and right striata were thawed, weighed and 
Statistical analysis of data
Individual comparisons were made using a two-tailed Student's t-test or paired t-test as appropriate. Where multiple comparisons were made, one-way ANOVA with posthoc Tukey's test for multiple comparisons was employed. Data for cell loss in vehicle and drug-treated groups are presented as the mean percentage change ± SEM; mean cell numbers were also compared. Biochemical data for monoamines is presented as the mean concentration ± SEM in ng/ml. In all figures, n values are shown in parenthesis. Differences were considered statistically significant at P<0.05 and all statistical data analysis was performed using GraphPad Prism v4.00 software (GraphPad software, San Diego, CA, USA).
Results
Effects of sub-chronic intranigral L-AP4 administration alone on the nigrostriatal system
In the current study, in all treatment groups the mean number of nigral TH-IR cells in the SNc in the contralateral hemisphere of the brain was comparable and not significantly different. Similarly, in all treatment groups the mean concentration of dopamine in the contralateral corpus striatum was comparable and not significantly different between treatment groups.
In sham-lesioned animals, no significant losses of TH-IR stained cells was observed in the SNc, nor were any significant changes observed in the levels of striatal dopamine, as shown in Figure 1A and 1B. Furthermore, no significant loss of striatal DOPAC or HVA was observed (Table 1) and, no significant changes in striatal DA turnover were seen ( Figure 1C ).
To investigate the effect of L-AP4 alone on the nigrostriatal system, shamlesioned animals were treated sub-chronically (7 days) with 10 nmol/4µl L-AP4. Figure 1A shows clearly that sub-chronic intranigral treatment with L-AP4 results in no significant loss of nigral TH-IR cells in the ipsilateral SNc. Consistent with this, sub-chronic (7 day) intranigral treatment with 10 nmol/4µl L-AP4 in sham-lesioned animals had no significant effect on the concentration of dopamine in the ipsilateral corpus striatum, as shown in Figure 1B . Moreover, no significant effects were observed on striatal concentrations of DOPAC or HVA between the ipsilateral and contralateral striata (Table 1) ; nor were any changes in striatal dopamine turnover observed, as clearly shown in Figure 1C . To illustrate these data, representative photomicrographs of nigral TH-IR cells from both groups are shown in Fig 6A and Significant reductions were also observed in the levels of striatal DOPAC and HVA (P<0.01, Table 1 ). Infusion of 6-OHDA caused a marked and significant increase in striatal dopamine metabolism when comparing the ipsilateral and contralateral striata (14.23 ± 2.49 vs. 10.53 ± 0.79 pmol x100; P<0.05), as shown in Figure 2D .
To investigate the neuroprotective potential of L-AP4, 6-OHDA-lesioned animals were intranigrally administered 2, 10, or 50 nmol L-AP4 in an injection volume of 4 µl daily over a period of 7 days. In this treatment group, the initial injection of L-AP4 was made one hour prior to the infusion of the 6-OHDA 14.89 ± 1.21 vs. 6.42 ± 0.89 ng/ml; P<0.05; 10 nmol/ 4 µl: 10.52 ± 0.34 vs. 6.42 ± 0.89 ng/ml; P<0.01; Figure 2C ). The restoration of striatal dopamine was maximal in animals treated with 10 nmol / 4 µl L-AP4, as no significant difference was found between the mean dopamine concentration in the ipsilateral and contralateral striata in this treatment group (11.31 ± 0.23 vs. 10.52 ± 0.34 ng/ml; P>0.05). It should be noted, however, that a significant loss of striatal dopamine was still observed when comparing the ipsilateral and contralateral striata within the 2 nmol/4 µl L-AP4-treated group (17.96 ± 0.83 vs. 14.89 ± 1.21 ng/ml; P<0.05). Thus, 6-OHDA still induces a loss of striatal dopamine in these animals, but this is markedly and significantly reduced when compared to the depletion seen in vehicle-treated animals.
In animals treated with 50 nmol L-AP4 the mean striatal dopamine concentration in the lesioned striata was not significantly different from vehicle-treated animals (4.06 ± 0.89 vs. 6.42 ± 0.89 ng/ml; P>0.05; Figure 2C ), in good agreement with the data collected for nigral TH-IR cells. Similar results were observed for striatal concentrations of DOPAC and HVA in all the L-AP4-treated groups (Table 1 ).
In terms of dopamine metabolism, treatment with 2 and 10 nmol/ 4 µl L-AP4
completely blocked the increase in the DOPAC/HVA: DA ratio observed in vehicletreated animals. These data suggest that the neuroprotective effects of L-AP4 on striatal monoamines are not due to increases in metabolic activity by the surviving nigral TH-IR cells. In contrast, in the 50 nmol/ 4 µl treated group a significant increase in dopamine turnover was observed in the ipsilateral striata when compared to the contralateral side (25.94 ± 3.18 vs. 17.18 ± 0.70 pmol x100; P<0.05, Figure   2D ). This increase is similar to that observed in vehicle-treated animals and is consistent with the absence of a neuroprotective effect at this concentration of L-AP4.
Since neuroprotection by L-AP4 appears to be maximal in animals treated with 10 nmol/4 µl L-AP4, this concentration was used in all subsequent experiments.
Acute treatment with L-AP4 protects the nigrostriatal system against 6-OHDA toxicity in vivo G-protein-coupled receptor functions, including mGluR functions, are tightly linked to receptor membrane expression and trafficking, which are regulated by G-protein receptor kinases (GRKs) and second messenger-dependent kinases, respectively (Mundell et al, 2004a) . This has been well characterised for Group I mGluR, but much less is known about desensitisation and internalisation of Group III mGluR.
Previous in situ studies have shown that Group III mGluR as a whole undergo heterologous desensitisation through a protein kinase A and C (PKA/PKC)-dependent mechanism (Cai et al, 2001 ). In support of this, the reversal of akinesia following i. Figure 6H . Acute treatment with 10 nmol/4 µl L-AP4 also significantly attenuated the reduction of striatal dopamine in the ipsilateral striata compared to vehicle-treated animals (12.03 ± 0.28 vs. 6.42 ± 0.89 ng/ml, respectively; P<0.01) and this also was not significantly different from sub-chronically treated animals, as shown in Figure 3C (12.03 ± 0.28 vs. 10.52 ± 0.34 ng/ml, respectively; P>0.05). Acute treatment with 10 nmol L-AP4 significantly reduced the fall in striatal DOPAC and HVA induced by 6-OHDA, and again this was not significantly different to that observed in sub-chronically treated animals (Table 1) . Furthermore, acute treatment with L-AP4 also completely blocked the 6-OHDA induced increases in striatal dopamine turnover, similar to that observed following sub-chronic treatment with this agonist ( Figure 3D ).
Neuroprotection of the nigrostriatal system following L-AP4 is reversed by coadministration with MSOP in 6-OHDA lesioned animals
To investigate if the neuroprotection of the nigrostriatal system by L-AP4 observed in the current study is mediated through Group III mGluR, 6-OHDA-lesioned animals received sub-chronic intranigral injections of 10 nmol L-AP4 co-administered with 50 nmol of the selective Group III mGluR antagonist MSOP in an injection volume of 4 µl. In a separate group, MSOP was administered alone to determine the effect of Group III mGluR blockade in vivo on the lesion induced by 6-OHDA. In these experiments, MSOP and L-AP4 were co-administered in a final injection volume of 4 µl, whilst MSOP was administered alone in an injection volume of 4 µl. As before, drug injections were made one hour prior to infusion of the 6-OHDA neurotoxin.
Thus, on the first day of treatment animals in these groups received two injections of 4 µl each giving a total volume of 8 µl. Subsequently, animals received a single unilateral injection daily of either L-AP4 + MSOP or MSOP alone in an injection volume of 4 µl for seven consecutive days Interestingly, Figure 4A shows that in 6-OHDA lesioned animals, sub-chronic intranigral administration of 50 nmol/4 µl MSOP alone slightly enhanced the mean percentage loss of nigral TH-IR cells induced by 6-OHDA (65.62 ± 1.61% vs. 77.23 ± 3.42% P>0.01). Treatment with MSOP also appeared to slightly enhance the 6-OHDA-induced depletion of striatal dopamine in the ipsilateral striata (4.36 ± 1.07 vs.
6.42 ± 0.89 ng/ml) but this failed to reach statistical significance, as shown in Figure   4B . Similar results were observed for the 6-OHDA-induced depletion of DOPAC and HVA levels in the ipsilateral striatum (see Table 1 ). Moreover, administration of MSOP did not block the 6-OHDA-induced increases in striatal dopamine turnover seen following 6-OHDA lesioning, as shown in Figure 4C .
In subsequent drug studies, co-administration of MSOP with L-AP4 led to a complete reversal of the previously observed neuroprotective effects of L-AP4 on nigral TH-IR cells (80.5 ± 2.1% vs. 33.9 ± 4.2%; P<0.01, Figure 4A ). Consistent with our data for MSOP alone, co-administration of MSOP with L-AP4 slightly enhanced the 6-OHDA lesion such that the mean percentage loss of nigral TH-IR cells was significantly greater than that observed in vehicle-treated animals (65.62 ± 1.61% vs.
80.5 ± 2.1%; P<0.05, Figure 4A ). To illustrate this, representative photomicrographs of TH-IR in the SNc from each treatment group are shown in Figure 7 panels A-D respectively. Similarly, the prevention of striatal dopamine depletion in the ipsilateral striata previously observed with L-AP4 alone was fully reversed by co-administration of MSOP (4.87 ± 1.32 vs. 4.36 ± 1.07 ng/ml; P>0.05). However, the presence of MSOP did not significantly enhance the depletion of striatal dopamine (4.87 ± 1.32 vs. 6.42 ± 0.89 ng/ml; P>0.05). Moreover, the increase in striatal dopamine metabolism, which was blocked by L-AP4 alone, was completely reversed by coadministration with MSOP, as shown in Figure 4C .
Sub-chronic intranigral treatment with L-AP4 slows 6-OHDA-mediated nigrostriatal degeneration in animals already undergoing nigrostriatal degeneration
The neuroprotective effect of L-AP4 may depend on its administration prior to lesioning with 6-OHDA. Therefore, to investigate if L-AP4 is neuroprotective or can "rescue" nigrostriatal neurones following 6-OHDA lesioning, animals were lesioned with 6-OHDA and left for 7 days to allow degeneration of the nigrostriatal tract to proceed. After 7 days, animals were then treated sub-chronically (7 days) with 10 nmol/4 µl L-AP4. As before, animals received single unilateral injections of L-AP4 in a final injection volume of 4 µl for seven consecutive days. Figure 5A shows that in animals treated with drug vehicle starting 7 days after the infusion of 6-OHDA into the SNc there is a significantly increased loss of nigral TH-IR cells compared to that seen in vehicle-treated animals sacrificed seven days post-6-OHDA lesioning (77.20 ± 1.55 vs. 68.75 ± 1.95%; P<0.01, Figure 5A ) and depletion of striatal dopamine (2.079 ± 0.85 vs. 6.42 ± 0.89 ng/ml; P<0.001, Figure 5C ) and DOPAC and HVA (P<0.01, Table 1 ). Furthermore, there is a very significant increase in striatal dopamine turnover in these animals, as shown in Figure 5D . These data suggest the presence of a continued progressive lesion of the nigrostriatal system after the initial insult, consistent with previous observations in this model (Stanic et al, 2003) . In animals treated sub-chronically with intranigral injections of 10 nmol/4 µl L-AP4 7 days after 6-OHDA administration, the mean percentage loss of nigral TH-IR cells was found not to be significantly different from that observed in vehicle-treated animals although a trend towards increased neuroprotection was observed (71.57 ± 9.10 vs. 77.20 ± 1.55%; P>0.05; Figure 5A ). Furthermore, in all regions of the SNc the mean percentage loss of nigral TH-IR cells was not significantly different to vehicle-treated animals as shown in figure 5B . Importantly, the small sample size of this group must be considered when interpreting these data. Interestingly however, the mean percentage loss of nigral TH-IR in L-AP4-treated animals is not significantly different from that observed in animals sacrificed 7 days post 6-OHDA-lesion, the time point at which drug or vehicle-treatment started (71.57 ± 9.10 vs. 65.62 ± 1.61%; P>0.05, Figure 5A ). To illustrate, this representative photomicrographs are shown in Figure 7 panels E and F. In contrast, the depletion of striatal dopamine in the ipsilateral striatum was significantly reduced in L-AP4-treated animals compared to vehicle-treated controls (8.067 ± 0.81 vs. 2.079 ± 0.85 ng/ml; P<0.001, Figure 5C ) and the depletion of dopamine in L-AP4-treated animals was not significantly different from that observed in vehicle-treated animals sacrificed 7 days post 6-OHDA-lesion (8.067 ± 0.81 vs. 6.42 ± 0.89 ng/ml; P>0.05, Fig 5C) . Similar effects were observed with the mean concentrations of DOPAC and HVA (Table 1) . There was however, a significant increase in striatal dopamine turnover in the L-AP4-treated animals as shown in Figure 5D , although this was not as marked as observed in vehicle-treated animals
Discussion
In this study a rodent 6-OHDA model of PD was employed to investigate the potential neuroprotective effects of selective activation of Group III mGluR by the Group III mGluR agonist L-AP4. Consistent with our previous preliminary observations we report that intranigral administration of L-AP4 is significantly neuroprotective against 6-OHDA toxicity in vivo in a clear concentration-dependent manner. Furthermore, this neuroprotective effect is observed following either acute or sub-chronic treatment and is reversed by co-application of the selective Group III mGluR antagonist MSOP, indicating a Group III mGluR-mediated mechanism of action.
These data are consistent with previous reports of a neuroprotective action of L-AP4 against glutamate-mediated toxicity both in vitro and in vivo (Lafon-Cazal et al, 1999b; Bruno et al, 2000) and very recent data reported by Jiang and colleagues (2006) , who demonstrated that L-AP4 is neuroprotective against rotenone toxicity in vitro, providing evidence for a neuroprotective effect of selective Group III mGluR activation in an experimental model of PD. To our knowledge, the current study is the first to document such an action for L-AP4 in an experimental model of PD in vivo.
Theoretically, the decrease in nigral TH-IR cells and the neuroprotective effects of L-AP4 could be due to transient atrophy of cells and downregulation of TH expression rather than true cell death and neuroprotection. We have addressed this possibility by staining sections adjacent to those stained for TH from vehicle-treated lesioned animals for the specific neuronal marker NeuN. From these sections we observed that infusion of 6-OHDA into the SNc produces a similar reduction of NeuN-IR cells compared to TH-IR cells (65.62 ± 1.61% vs. 73.31 ± 4.63%). Thus, the observed loss of TH-IR cells can be attributed to cell death and not simple downregulation of TH in atrophic neurones. Accordingly, the observed neuroprotective effects of L-AP4 cannot be explained by TH up-regulation. Importantly, L-AP4 treatment also attenuated the 6-OHDA-induced depletion of striatal dopamine and its metabolites, which indicates preservation of axonal projections. The observation that L-AP4 also blocks 6-OHDA-induced increases in striatal dopamine turnover suggests that the prevention of dopamine depletion by L-AP4 is due to neuroprotection of dopamine terminals rather than increased dopamine metabolism by the surviving nigral TH-IR cells. Furthermore, because of the short time between 6-OHDA lesioning and HPLC measurements (7 days post-6-OHDA lesion) it is unlikely that the preservation of striatal dopamine could be explained by sprouting of the remaining axonal projections, which has been shown to occur 4 weeks after 6-OHDA lesioning (Stanic et al, 2003) . Taken together these data support a true neuroprotective effect of L-AP4
The neuroprotective action of L-AP4 shows a bell-shaped profile with an absence of neuroprotection at higher concentrations. Interestingly, similar findings have been reported in vitro against NMDA-toxicity in striatal GABAergic neuronal cultures (Lafon-Cazal et al, 1999a) . Indeed, , high concentrations of L-AP4 enhanced NMDA toxicity, which was suggested to be due to inhibition of γ -aminobutyric acid (GABA)
release by activation of presynaptic mGluR7 removing the hyperpolarising influence of GABA on striatal neurones thus sensitising them to excitotoxicity (Lafon-Cazal et al, 1999a) . It is noteworthy that a similar role for presynaptic Group III mGluR as negative modulators of GABA release in both the SNc (Giustizeri et al, 2005) and SNr (Wittmann et al, 2001; 2002) has been reported, consistent with data reporting localisation of mGluR7 receptor protein at symmetric (inhibitory) synapses in the SNr (Kosiniski et al, 1999) . Moreover, synaptically released GABA in the both the SNc and the SNr is implicated in the control of dopaminergic cell firing (Wittmann et al, 2001; 2002; Giustizieri et al, 2005) . Thus, it is conceivable that when high concentrations of L-AP4 are administered intranigrally, GABA transmission is inhibited by activation of presynaptic mGluR7 on SNr GABAergic neurones forming axo-axonic synapses on glutamatergic STN axon terminals, thereby enhancing glutamatergic transmission onto nigral neurones. This is anatomically feasible, as the SNc sends dendrites deep into the SNr (Iribe et al., 1999) and STN axon terminals are known to terminate on dopaminergic dendrites in the SNr (Smith et al, 1990 ).
However, responses mediated by Group III mGluR are sensitive to dopamine depletion; which appears to reduces the ability of L-AP4 to inhibit GABA release in vitro (Wittmann et al, 2002) . Importantly, inhibition of excitatory transmission in the SNr by L-AP4 was not affected by dopamine depletion (Wittmann et al, 2002) .
Therefore, in the Parkinsonian brain inhibition of GABA release by activation of Group III mGluR on GABAergic nigral neurones may be reduced by dopamine depletion. Importantly, the extent of the lesion appears to critically determine the function of the mGluR subtypes involved. In the current study, the level of dopamine depletion induced by 6-OHDA (<70%) may not sufficiently affect mGluR7-mediated inhibition of GABA release by high concentrations of L-AP4, therefore perturbation of GABAergic inputs to nigral dopaminergic neurones may still explain the absence of neuroprotection. Interestingly, 6-OHDA toxicity is not enhanced by high concentrations of L-AP4, as observed in vitro (Lafon-Cazal et al, 1999a) .
Speculatively, this could be attributed to the Group III mGluR-mediated reduction of glutamate release balancing out reductions in GABA transmission.
Post-lesion treatment with L-AP4 did not significantly protect nigral TH-IR cells, although a trend towards increased protection was observed. This may be explained in terms of the time course of DA neuronal death in the 6-OHDA model. Evidence suggests this occurs in two phases, an initial rapid phase of cell death, followed by a progressive loss of the remaining neurones over time (Stanic et al, 2003) . Thus, 7 days post-6-OHDA lesion may be too late to provide significant protection of nigral TH-IR cells as the majority of cell death may have already occurred. Interestingly, , post-lesion treatment with L-AP4 significantly prevents further depletion of dopamine in the ipsilateral striatum , which is difficult to reconcile with the absence of protection of nigral TH-IR cells.. Thus, it cannot be definitively confirmed that L-AP4
is neuroprotective when administered post-lesion; although perhaps if L-AP4 treatment were started earlier significant neuroprotection may be observed.
However, these data are consistent with a previous study in the same model in which the selective Group II mGluR agonist LY379268 was reported to provide a small, but not significant protection of nigral TH-IR cells in animals undergoing nigrostriatal degeneration, which was associated with reduced but significantly increased dopamine turnover (Murray et al, 2002) .
Importantly, the neuroprotection mediated by L-AP4 is completely reversed by co-administration with the selective Group III mGluR antagonist MSOP, which indicates that this neuroprotection is mediated through a Group III mGluR-dependent mechanism, further supporting a critical role of this class of mGluR. However, since L-AP4 is a broad-spectrum agonist with activity at all Group III mGluR subtypes (Schoepp et al, 1999) , we cannot definitively state the Group III mGluR subtypes through which L-AP4 exerts this effect. Based on the high potency with which L-AP4 inhibits excitatory transmission in the SNc in vitro, mGluR4 and mGluR8 are likely candidates (Valenti et al, 2005) . Recent studies in vitro suggest that mGluR4 but not mGluR8 mediates this effect (Valenti et al, 2005) . This is interesting when considering the potential mechanisms of neuroprotection by L-AP4. Neuroprotection following activation of Group III mGluR is suggested to result from presynaptic inhibition of glutamate release (Valenti et al, 2003) . In support of this, L-AP4 has been reported to inhibit evoked EPSCs at synapses onto midbrain dopaminergic neurones, with a clear presynaptic mechanism of action (Wigmore and Lacey, 1998; Katayama et al, 2003) . However, previous studies have also reported a significant contribution of glial cells to neuroprotection induced by mGluR agonists (Bruno et al, 1998) . Both astroglia and microglia are known to express functional Group III mGluR, thus speculatively activation of either mGluR4 or 8 expressed on these cell types may contribute to neuroprotection by L-AP4 in our model in which significant gliosis occurs in response to 6-OHDA-induced cell death. In support of this concept, activation of astroglial and microglial Group III mGluR has recently been shown to be neuroprotective in vitro (Taylor et al, 2003; Yao et al, 2005) . Thus, it will be important in future studies to define the exact subtype of Group III mGluR that mediates neuroprotection by L-AP4 in vivo. Interestingly, evidence from in vitro studies suggests that positive allosteric modulators selective for mGluR4 are also neuroprotective in vitro (Maj et al, 2003) . This is interesting since the use of direct mGluR agonists like L-AP4 as a chronic treatment for PD is likely to be limited by adverse effects associated with excessive activation of the receptor, including receptor desensitization and loss of the neuronal activity dependence of receptor activation by pulsatile release of neurotransmitter (Conn et al, 2003) . In conclusion, the findings presented herein, together with complementary data published during the course of the present study suggesting that the mGluR4-selective positive allosteric modulator PHCCC is neuroprotective against MPTP-induced nigrostriatal damage in mice (Battaglia et al 2006) , provide compelling evidence that selective activation of Group III mGluR is neuroprotective in vivo in experimental models of parkinsonism, which may have implications for the future treatment of PD. 
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